Details of the Drug

General Information of Drug (ID: DMM4FJ3)

Drug Name
Finerenone
Synonyms
UNII-DE2O63YV8R; BAY 94-8862; 1050477-31-0; BAY94-8862; DE2O63YV8R; Finerenone [USAN:INN]; Finerenone (JAN/USAN/INN); SCHEMBL8157011; GTPL8678; DTXSID10146928; J3.584.878I; D10633; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-;1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; 1,6-Naphthyridine-3-carboxamide, 4-(4-cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-, (4S)-; (4S)-4-(4-cyano-2-metho
Indication
Disease Entry ICD 11 Status REF
Chronic kidney disease GB61 Approved [1]
Diabetic nephropathy GB61.Z Phase 3 [2]
Affected Organisms
Humans
ATC Code
C03DA05: Finerenone
C03DA: Aldosterone antagonists
C03D: ALDOSTERONE ANTAGONISTS AND OTHER POTASSIUM-SPARING AGENTS
C03: DIURETICS
C: CARDIOVASCULAR SYSTEM
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 378.4
Logarithm of the Partition Coefficient (xlogp) 2.4
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
Absorption AUC
The area under the plot of plasma concentration (AUC) of drug is 2.82 mgh/L [3]
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 351 mcg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 1.5 h [3]
Clearance
The sytemic clearance of drug is 25 L/h [4]
Elimination
The majority of the dose recovered in urine was in the form of the M2, M3 (47.8%), and M4 metabolites; <1.3% of the dose recovered in the urine was as the unchanged parent compound [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 - 3 hours [3]
Metabolism
The drug is metabolized via the CYP3A4 and CYP2C8 [3]
Vd
The volume of distribution (Vd) of drug is 52.6 L [4]
Chemical Identifiers
Formula
C21H22N4O3
IUPAC Name
(4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide
Canonical SMILES
CCOC1=NC=C(C2=C1[C@@H](C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C
InChI
InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
InChIKey
BTBHLEZXCOBLCY-QGZVFWFLSA-N
Cross-matching ID
PubChem CID
60150535
ChEBI ID
CHEMBL2181927
CAS Number
1050477-31-0
UNII
DE2O63YV8R
DrugBank ID
DB16165
TTD ID
D0NV5O
Drug-Molecule Activity Atlas (DMA)NEW Click to Jump to the Detailed DMA Information of This Drug
Drug ADMET Endpoint Profile (DAE)NEW Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Mineralocorticoid receptor (MR) TT26PHO MCR_HUMAN Antagonist [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Chronic kidney disease
ICD Disease Classification GB61
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Mineralocorticoid receptor (MR) DTT NR3C2 7.31E-01 -5.31E-04 -1.53E-03
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 215341.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro. Drug Metab Dispos. 2018 Nov;46(11):1546-1555. doi: 10.1124/dmd.118.083337. Epub 2018 Aug 31.
4 FDA Approved Drug Products: Kerendia (Finerenone) Oral Tablet